Search

Your search keyword '"Hill, Adrian V. S."' showing total 172 results
Start Over Author "Hill, Adrian V. S." Journal plos one
172 results on '"Hill, Adrian V. S."'

1. Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites

Author

Kolli, Surendra Kumar, primary, Salman, Ahmed M., additional, Ramesar, Jai, additional, Chevalley-Maurel, Severine, additional, Kroeze, Hans, additional, Geurten, Fiona G. A., additional, Miyazaki, Shinya, additional, Mukhopadhyay, Ekta, additional, Marin-Mogollon, Catherin, additional, Franke-Fayard, Blandine, additional, Hill, Adrian V. S., additional, and Janse, Chris J., additional

Published
2021
Full Text
View/download PDF

2. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Author

Borrow, Ray, Tiono, Alfred B., Nébié, Issa, Anagnostou, Nicholas, Coulibaly, Aboubacar S., Bowyer, Georgina, Lam, Erika, Bougouma, Edith C., Ouedraogo, Alphonse, Yaro, Jean Baptist B., Barry, Aïssata, Roberts, Rachel, Rampling, Tommy, Bliss, Carly, Hodgson, Susanne, Lawrie, Alison, Ouedraogo, Amidou, Imoukhuede, Egeruan Babatunde, Ewer, Katie J., Viebig, Nicola K., Diarra, Amidou, Leroy, Odile, Bejon, Philip, Hill, Adrian V. S., and Sirima, Sodiomon B.

Subjects
0301 basic medicine, Male, Viral Diseases, Physiology, T-Lymphocytes, Kaplan-Meier Estimate, Biochemistry, law.invention, chemistry.chemical_compound, White Blood Cells, 0302 clinical medicine, Randomized controlled trial, law, Animal Cells, Zoonoses, Immune Physiology, Clinical endpoint, Medicine and Health Sciences, Public and Occupational Health, 030212 general & internal medicine, Enzyme-Linked Immunoassays, Vaccines, Multidisciplinary, Immune System Proteins, Malaria vaccine, T Cells, Immunogenicity, Vaccination and Immunization, 3. Good health, Infectious Diseases, Medicine, Female, Cellular Types, Research Article, Neglected Tropical Diseases, medicine.medical_specialty, Infectious Disease Control, Rabies, Immune Cells, Science, Plasmodium falciparum, Immunology, Enzyme-Linked Immunosorbent Assay, Vaccinia virus, Research and Analysis Methods, complex mixtures, Antibodies, 03 medical and health sciences, Double-Blind Method, Internal medicine, parasitic diseases, Malaria Vaccines, medicine, Parasitic Diseases, Humans, Antigens, Immunoassays, Blood Cells, business.industry, Infant, Biology and Life Sciences, Proteins, Cell Biology, medicine.disease, Tropical Diseases, Kenya, Malaria, Clinical trial, Regimen, 030104 developmental biology, chemistry, Leukocytes, Mononuclear, Immunologic Techniques, Adenoviruses, Simian, Preventive Medicine, Vaccinia, business
Abstract

BackgroundHeterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified Vaccinia Virus Ankara (MVA) vectored vaccines is a strategy previously shown to provide substantial protective efficacy against P. falciparum infection in United Kingdom adult Phase IIa sporozoite challenge studies (approximately 20-25% sterile protection with similar numbers showing clear delay in time to patency), and greater point efficacy in a trial in Kenyan adults.MethodologyWe conducted the first Phase IIb clinical trial assessing the safety, immunogenicity and efficacy of ChAd63 MVA ME-TRAP in 700 healthy malaria exposed children aged 5-17 months in a highly endemic malaria transmission area of Burkina Faso.ResultsChAd63 MVA ME-TRAP was shown to be safe and immunogenic but induced only moderate T cell responses (median 326 SFU/106 PBMC (95% CI 290-387)) many fold lower than in previous trials. No significant efficacy was observed against clinical malaria during the follow up period, with efficacy against the primary endpoint estimate by proportional analysis being 13.8% (95%CI -42.4 to 47.9) at sixth month post MVA ME-TRAP and 3.1% (95%CI -15.0 to 18.3; p = 0.72) by Cox regression.ConclusionsThis study has confirmed ChAd63 MVA ME-TRAP is a safe and immunogenic vaccine regimen in children and infants with prior exposure to malaria. But no significant protective efficacy was observed in this very highly malaria-endemic setting.Trial registrationClinicalTrials.gov NCT01635647. Pactr.org PACTR201208000404131.

Published
2018

3. First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children

Author

Tiono, Alfred B., primary, Nébié, Issa, additional, Anagnostou, Nicholas, additional, Coulibaly, Aboubacar S., additional, Bowyer, Georgina, additional, Lam, Erika, additional, Bougouma, Edith C., additional, Ouedraogo, Alphonse, additional, Yaro, Jean Baptist B., additional, Barry, Aïssata, additional, Roberts, Rachel, additional, Rampling, Tommy, additional, Bliss, Carly, additional, Hodgson, Susanne, additional, Lawrie, Alison, additional, Ouedraogo, Amidou, additional, Imoukhuede, Egeruan Babatunde, additional, Ewer, Katie J., additional, Viebig, Nicola K., additional, Diarra, Amidou, additional, Leroy, Odile, additional, Bejon, Philip, additional, Hill, Adrian V. S., additional, and Sirima, Sodiomon B., additional

Published
2018
Full Text
View/download PDF

4. Enhanced Vaccine-Induced CD8+ T Cell Responses to Malaria Antigen ME-TRAP by Fusion to MHC Class II Invariant Chain

Author

Spencer, Alexandra J., Cottingham, Matthew G., Jenks, Jennifer A., Longley, Rhea J., Capone, Stefania, Colloca, Stefano, Folgori, Antonella, Cortese, Riccardo, Bregu, Migena, Hill, Adrian V. S., NICOSIA, Alfredo, Spencer, Alexandra J., Cottingham, Matthew G., Jenks, Jennifer A., Longley, Rhea J., Capone, Stefania, Colloca, Stefano, Folgori, Antonella, Cortese, Riccardo, Nicosia, Alfredo, Bregu, Migena, and Hill, Adrian V. S.

Subjects
Male, Immune Cells, Recombinant Fusion Proteins, Immunology, Genetic Vectors, Antigens, Protozoan, CD8-Positive T-Lymphocytes, complex mixtures, White Blood Cells, Malaria Vaccine, Animal Cells, Malaria Vaccines, Medicine and Health Sciences, Animals, Humans, Plasmodium Malariae, Malaria, Falciparum, Protozoans, Vaccines, Mice, Inbred ICR, Biochemistry, Genetics and Molecular Biology (all), Blood Cells, Recombinant Vaccines, Animal, T Cells, Medicine (all), Organisms, Malarial Parasites, Histocompatibility Antigens Class II, Biology and Life Sciences, CD8-Positive T-Lymphocyte, Cell Biology, Chicken, Vaccination and Immunization, Macaca mulatta, Parasitic Protozoans, Antigens, Differentiation, B-Lymphocyte, Mice, Inbred C57BL, Agricultural and Biological Sciences (all), Female, Immunization, Genetic Vector, Cellular Types, Chickens, Human, Recombinant Fusion Protein, Research Article
Abstract

The orthodox role of the invariant chain (CD74; Ii) is in antigen presentation to CD4+ T cells, but enhanced CD8+ T cells responses have been reported after vaccination with vectored viral vaccines encoding a fusion of Ii to the antigen of interest. In this study we assessed whether fusion of the malarial antigen, ME-TRAP, to Ii could increase the vaccine-induced CD8+ T cell response. Following single or heterologous prime-boost vaccination of mice with a recombinant chimpanzee adenovirus vector, ChAd63, or recombinant modified vaccinia virus Ankara (MVA), higher frequencies of antigen-specific CD4+ and CD8+ T cells were observed, with the largest increases observed following a ChAd63-MVA heterologous prime-boost regimen. Studies in non-human primates confirmed the ability of Ii-fusion to augment the T cell response, where a 4-fold increase was maintained up to 11 weeks after the MVA boost. Of the numerous different approaches explored to increase vectored vaccine induced immunogenicity over the years, fusion to the invariant chain showed a consistent enhancement in CD8+ T cell responses across different animal species and may therefore find application in the development of vaccines against human malaria and other diseases where high levels of cell-mediated immunity are required.

Published
2014

5. A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS

Author

Richie, Thomas L., de Barra, Eoghan, Hodgson, Susanne H., Ewer, Katie J., Bliss, Carly M., Hennigan, Kerrie, Collins, Ann, Berrie, Eleanor, Lawrie, Alison M., Gilbert, Sarah C., Nicosia, Alfredo, McConkey, Samuel J., Hill, Adrian V. S., De Barra, Eoghan, Hodgson, Susanne H., Ewer, Katie J., Bliss, Carly M., Hennigan, Kerrie, Collins, Ann, Berrie, Eleanor, Lawrie, Alison M., Gilbert, Sarah C., Nicosia, Alfredo, Mcconkey, Samuel J., and Hill, Adrian V. S.

Subjects
Protozoan Proteins, lcsh:Medicine, Clinical trials, Antiparasitic Therapy, Vaccines, DNA, Medicine, lcsh:Science, Vaccines, Multidisciplinary, Recombinant Vaccines, biology, Malaria vaccine, Phase I clinical investigation, ELISPOT, Immunogenicity, Viral Vaccine, Medicine (all), Middle Aged, Vaccination and Immunization, 3. Good health, Circumsporozoite protein, Infectious Diseases, Female, Antibody, Human, Research Article, Adult, Adolescent, Immunology, complex mixtures, Antigen, Malaria Vaccine, Malaria Vaccines, Vaccine Development, Parasitic Diseases, Humans, Medicine and health sciences, Biochemistry, Genetics and Molecular Biology (all), business.industry, lcsh:R, Protozoan Protein, Biology and Life Sciences, Plasmodium falciparum, Viral Vaccines, biology.organism_classification, Virology, Malaria, Vector-Borne Diseases, Agricultural and Biological Sciences (all), Immunoglobulin G, Clinical medicine, biology.protein, Adenoviruses, Simian, lcsh:Q, business
Abstract

Background Plasmodium falciparum (P. falciparum) malaria remains a significant cause of mortality and morbidity throughout the world. Development of an effective vaccine would be a key intervention to reduce the considerable social and economic impact of malaria. Methodology We conducted a Phase Ia, non-randomized, clinical trial in 24 healthy, malaria-naïve adults of the chimpanzee adenovirus 63 (ChAd63) and modified vaccinia virus Ankara (MVA) replication-deficient viral vectored vaccines encoding the circumsporozoite protein (CS) of P. falciparum. Results ChAd63-MVA CS administered in a heterologous prime-boost regime was shown to be safe and immunogenic, inducing high-level T cell responses to CS. With a priming ChAd63 CS dose of 5×109 vp responses peaked at a mean of 1947 SFC/million PBMC (median 1524) measured by ELIspot 7 days after the MVA boost and showed a mixed CD4+/CD8+ phenotype. With a higher priming dose of ChAd63 CS dose 5×1010 vp T cell responses did not increase (mean 1659 SFC/million PBMC, median 1049). Serum IgG responses to CS were modest and peaked at day 14 post ChAd63 CS (median antibody concentration for all groups at day 14 of 1.3 µg/ml (range 0–11.9), but persisted throughout late follow-up (day 140 median antibody concentration groups 1B & 2B 0.9 µg/ml (range 0–4.7). Conclusions ChAd63-MVA is a safe and highly immunogenic delivery platform for the CS antigen in humans which warrants efficacy testing. Trial Registration ClinicalTrials.gov NCT01450280

Published
2014

6. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure

Author

Doolan, Denise L., Biswas, Sumi, Choudhary, Prateek, Elias, Sean C., Miura, Kazutoyo, Milne, Kathryn H., de Cassan, Simone C., Collins, Katharine A., Halstead, Fenella D., Bliss, Carly M., Ewer, Katie J., Osier, Faith H., Hodgson, Susanne H., Duncan, Christopher J. A., O?Hara, Geraldine A., Long, Carole A., Hill, Adrian V. S., and Draper, Simon J.

Subjects
Humoral Immune Response, lcsh:Medicine, Antibodies, Protozoan, Parasitemia, Immunoglobulin G, Medicine and Health Sciences, Malaria, Falciparum, lcsh:Science, Vaccines, Multidisciplinary, Recombinant Vaccines, Vaccination, Environmental exposure, Vaccination and Immunization, 3. Good health, Blood, Antibody, Research Article, Pan troglodytes, Plasmodium falciparum, Immunology, Antigens, Protozoan, Vaccinia virus, Biology, Adenoviridae, Immune system, Antigen, Species Specificity, Malaria Vaccines, Vaccine Development, parasitic diseases, medicine, Parasitic Diseases, Animals, Humans, lcsh:R, Immunity, Biology and Life Sciences, Environmental Exposure, medicine.disease, biology.organism_classification, Tropical Diseases, Virology, Immunity, Humoral, Malaria, Humoral Immunity, biology.protein, lcsh:Q
Abstract

The development of protective vaccines against many difficult infectious pathogens will necessitate the induction of effective antibody responses. Here we assess humoral immune responses against two antigens from the blood-stage merozoite of the Plasmodium falciparum human malaria parasite – MSP1 and AMA1. These antigens were delivered to healthy malaria-naive adult volunteers in Phase Ia clinical trials using recombinant replication-deficient viral vectors – ChAd63 to prime the immune response and MVA to boost. In subsequent Phase IIa clinical trials, immunized volunteers underwent controlled human malaria infection (CHMI) with P. falciparum to assess vaccine efficacy, whereby all but one volunteer developed low-density blood-stage parasitemia. Here we assess serum antibody responses against both the MSP1 and AMA1 antigens following i) ChAd63-MVA immunization, ii) immunization and CHMI, and iii) primary malaria exposure in the context of CHMI in unimmunized control volunteers. Responses were also assessed in a cohort of naturally-immune Kenyan adults to provide comparison with those induced by a lifetime of natural malaria exposure. Serum antibody responses against MSP1 and AMA1 were characterized in terms of i) total IgG responses before and after CHMI, ii) responses to allelic variants of MSP1 and AMA1, iii) functional growth inhibitory activity (GIA), iv) IgG avidity, and v) isotype responses (IgG1-4, IgA and IgM). These data provide the first in-depth assessment of the quality of adenovirus-MVA vaccine-induced antibody responses in humans, along with assessment of how these responses are modulated by subsequent low-density parasite exposure. Notable differences were observed in qualitative aspects of the human antibody responses against these malaria antigens depending on the means of their induction and/or exposure of the host to the malaria parasite. Given the continued clinical development of viral vectored vaccines for malaria and a range of other diseases targets, these data should help to guide further immuno-monitoring studies of vaccine-induced human antibody responses.

Published
2014

7. T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein

Author

Forbes, Emily K., de Cassan, Simone C., Llewellyn, David, Biswas, Sumi, Goodman, Anna L., Cottingham, Matthew G., Long, Carole A., Pleass, Richard J., Hill, Adrian V. S., Hill, Fergal, and Draper, Simon J.

Subjects
Mouse, Immune Cells, T-Lymphocytes, Immunology, Genetic Vectors, Plasmodium falciparum, lcsh:Medicine, Antigens, Protozoan, wc_500, Microbiology, qw_805, Vector Biology, Adenoviridae, Mice, Model Organisms, Adjuvants, Immunologic, Virology, Malaria Vaccines, Parasitic Diseases, Animals, lcsh:Science, Biology, Merozoite Surface Protein 1, qw_575, Vaccines, Mice, Inbred BALB C, T Cells, Complement C4b-Binding Protein, Vaccination, Receptors, IgG, lcsh:R, Immunity, Tropical Diseases (Non-Neglected), Animal Models, Plasmodium yoelii, Malaria, Protein Structure, Tertiary, Infectious Diseases, Medicine, Clinical Immunology, Female, lcsh:Q, Rabbits, Viral Vectors, Research Article
Abstract

Viral vectored vaccines have been shown to induce both T cell and antibody responses in animals and humans. However, the induction of even higher level T cell responses may be crucial in achieving vaccine efficacy against difficult disease targets, especially in humans. Here we investigate the oligomerization domain of the (Alpha)-chain of C4b-binding protein (C4 bp) as a candidate T cell "molecular adjuvant" when fused to malaria antigens expressed by human adenovirus serotype 5 (AdHu5) vectored vaccines in BALB/c mice. We demonstrate that i) C-terminal fusion of an oligomerization domain can enhance the quantity of antigen-specific CD4(+) and CD8(+) T cell responses induced in mice after only a single immunization of recombinant AdHu5, and that the T cells maintain similar functional cytokine profiles; ii) an adjuvant effect is observed for AdHu5 vectors expressing either the 42 kDa C-terminal domain of Plasmodium yoelii merozoite surface protein 1 (PyMSP1(42)) or the 83 kDa ectodomain of P. falciparum strain 3D7 apical membrane antigen 1 (PfAMA1), but not a candidate 128kDa P. falciparum MSP1 biallelic fusion antigen; iii) following two homologous immunizations of AdHu5 vaccines, antigen-specific T cell responses are further enhanced, however, in both BALB/c mice and New Zealand White rabbits no enhancement of functional antibody responses is observed; and iv) that the T cell adjuvant activity of C4 bp is not dependent on a functional Fc-receptor (Gamma)-chain in the host, but is associated with the oligomerization of small (

Published
2012

8. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years

Author

Doherty, T. Mark, Antrobus, Richard D., Lillie, Patrick J., Berthoud, Tamara K., Spencer, Alexandra J., McLaren, James E., Ladell, Kristin Ingrid, Lambe, Teresa, Milicic, Anita, Price, David, Hill, Adrian V. S., and Gilbert, Sarah C.

Subjects
Male, Viral Diseases, T-Lymphocytes, lcsh:Medicine, medicine.disease_cause, Influenza A virus, Cytotoxic T cell, lcsh:Science, Immune Response, Aged, 80 and over, Multidisciplinary, T Cells, Genetically Modified Organisms, Immunogenicity, Vaccination, hemic and immune systems, Middle Aged, Orthomyxoviridae, Infectious Diseases, medicine.anatomical_structure, Medicine, Female, Safety, Genetic Engineering, Research Article, Biotechnology, Influenza vaccine, Immune Cells, T cell, Molecular Sequence Data, Vaccinia virus, Biology, complex mixtures, Interferon-gamma, Viral Proteins, Vaccine Development, medicine, Humans, Amino Acid Sequence, Aged, Influenza A Virus, H3N2 Subtype, lcsh:R, Immunity, Viral Vaccines, Virology, Influenza, Nucleoproteins, Geriatrics, Immunology, Clinical Immunology, lcsh:Q, Memory T cell, CD8
Abstract

BACKGROUND: Current influenza vaccines have reduced immunogenicity and are of uncertain efficacy in older adults. We assessed the safety and immunogenicity of MVA-NP+M1, a viral-vectored influenza vaccine designed to boost memory T cell responses, in a group of older adults. METHODS: Thirty volunteers (aged 50-85) received a single intramuscular injection of MVA-NP+M1 at a dose of 1·5×10(8) plaque forming units (pfu). Safety and immunogenicity were assessed over a period of one year. The frequency of T cells specific for nucleoprotein (NP) and matrix protein 1 (M1) was determined by interferon-gamma (IFN-γ) ELISpot, and their phenotypic and functional properties were characterized by polychromatic flow cytometry. In a subset of M1-specific CD8(+) T cells, T cell receptor (TCR) gene expression was evaluated using an unbiased molecular approach. RESULTS: Vaccination with MVA-NP+M1 was well tolerated. ELISpot responses were boosted significantly above baseline following vaccination. Increases were detected in both CD4(+) and CD8(+) T cell subsets. Clonality studies indicated that MVA-NP+M1 expanded pre-existing memory CD8(+) T cells, which displayed a predominant CD27(+)CD45RO(+)CD57(-)CCR7(-) phenotype both before and after vaccination. CONCLUSIONS: MVA-NP+M1 is safe and immunogenic in older adults. Unlike seasonal influenza vaccination, the immune responses generated by MVA-NP+M1 are similar between younger and older individuals. A T cell-inducing vaccine such as MVA-NP+M1 may therefore provide a way to circumvent the immunosenescence that impairs routine influenza vaccination. TRIAL REGISTRATION: ClinicalTrials.gov NCT00942071.

Published
2012

15. A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS

Author

de Barra, Eoghan, primary, Hodgson, Susanne H., additional, Ewer, Katie J., additional, Bliss, Carly M., additional, Hennigan, Kerrie, additional, Collins, Ann, additional, Berrie, Eleanor, additional, Lawrie, Alison M., additional, Gilbert, Sarah C., additional, Nicosia, Alfredo, additional, McConkey, Samuel J., additional, and Hill, Adrian V. S., additional

Published
2014
Full Text
View/download PDF

16. Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure

Author

Biswas, Sumi, primary, Choudhary, Prateek, additional, Elias, Sean C., additional, Miura, Kazutoyo, additional, Milne, Kathryn H., additional, de Cassan, Simone C., additional, Collins, Katharine A., additional, Halstead, Fenella D., additional, Bliss, Carly M., additional, Ewer, Katie J., additional, Osier, Faith H., additional, Hodgson, Susanne H., additional, Duncan, Christopher J. A., additional, O’Hara, Geraldine A., additional, Long, Carole A., additional, Hill, Adrian V. S., additional, and Draper, Simon J., additional

Published
2014
Full Text
View/download PDF

17. 4-1BBL Enhances CD8+ T Cell Responses Induced by Vectored Vaccines in Mice but Fails to Improve Immunogenicity in Rhesus Macaques

Author

Spencer, Alexandra J., primary, Furze, Julie, additional, Honeycutt, Jared D., additional, Calvert, Alice, additional, Saurya, Saroj, additional, Colloca, Stefano, additional, Wyllie, David H., additional, Gilbert, Sarah C., additional, Bregu, Migena, additional, Cottingham, Matthew G., additional, and Hill, Adrian V. S., additional

Published
2014
Full Text
View/download PDF

18. External Quality Assurance of Malaria Nucleic Acid Testing for Clinical Trials and Eradication Surveillance

Author

Murphy, Sean C., primary, Hermsen, Cornelus C., additional, Douglas, Alexander D., additional, Edwards, Nick J., additional, Petersen, Ines, additional, Fahle, Gary A., additional, Adams, Matthew, additional, Berry, Andrea A., additional, Billman, Zachary P., additional, Gilbert, Sarah C., additional, Laurens, Matthew B., additional, Leroy, Odile, additional, Lyke, Kristen E., additional, Plowe, Christopher V., additional, Seilie, Annette M., additional, Strauss, Kathleen A., additional, Teelen, Karina, additional, Hill, Adrian V. S., additional, and Sauerwein, Robert W., additional

Published
2014
Full Text
View/download PDF

19. Dry-Coated Live Viral Vector Vaccines Delivered by Nanopatch Microprojections Retain Long-Term Thermostability and Induce Transgene-Specific T Cell Responses in Mice

Author

Pearson, Frances E., primary, McNeilly, Celia L., additional, Crichton, Michael L., additional, Primiero, Clare A., additional, Yukiko, Sally R., additional, Fernando, Germain J. P., additional, Chen, Xianfeng, additional, Gilbert, Sarah C., additional, Hill, Adrian V. S., additional, and Kendall, Mark A. F., additional

Published
2013
Full Text
View/download PDF

20. Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe

Author

Sheehy, Susanne H., primary, Spencer, Alexandra J., additional, Douglas, Alexander D., additional, Sim, B. Kim Lee, additional, Longley, Rhea J., additional, Edwards, Nick J., additional, Poulton, Ian D., additional, Kimani, Domtila, additional, Williams, Andrew R., additional, Anagnostou, Nicholas A., additional, Roberts, Rachel, additional, Kerridge, Simon, additional, Voysey, Merryn, additional, James, Eric R., additional, Billingsley, Peter F., additional, Gunasekera, Anusha, additional, Lawrie, Alison M., additional, Hoffman, Stephen L., additional, and Hill, Adrian V. S., additional

Published
2013
Full Text
View/download PDF

22. Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults

Author

Ogwang, Caroline, primary, Afolabi, Muhammed, additional, Kimani, Domtila, additional, Jagne, Ya Jankey, additional, Sheehy, Susanne H., additional, Bliss, Carly M., additional, Duncan, Christopher J. A., additional, Collins, Katharine A., additional, Garcia Knight, Miguel A., additional, Kimani, Eva, additional, Anagnostou, Nicholas A., additional, Berrie, Eleanor, additional, Moyle, Sarah, additional, Gilbert, Sarah C., additional, Spencer, Alexandra J., additional, Soipei, Peninah, additional, Mueller, Jenny, additional, Okebe, Joseph, additional, Colloca, Stefano, additional, Cortese, Riccardo, additional, Viebig, Nicola K., additional, Roberts, Rachel, additional, Gantlett, Katherine, additional, Lawrie, Alison M., additional, Nicosia, Alfredo, additional, Imoukhuede, Egeruan B., additional, Bejon, Philip, additional, Urban, Britta C., additional, Flanagan, Katie L., additional, Ewer, Katie J., additional, Chilengi, Roma, additional, Hill, Adrian V. S., additional, and Bojang, Kalifa, additional

Published
2013
Full Text
View/download PDF

23. The Ratio of Monocytes to Lymphocytes in Peripheral Blood Correlates with Increased Susceptibility to Clinical Malaria in Kenyan Children

Author

Warimwe, George M., primary, Murungi, Linda M., additional, Kamuyu, Gathoni, additional, Nyangweso, George M., additional, Wambua, Juliana, additional, Naranbhai, Vivek, additional, Fletcher, Helen A., additional, Hill, Adrian V. S., additional, Bejon, Philip, additional, Osier, Faith H. A., additional, and Marsh, Kevin, additional

Published
2013
Full Text
View/download PDF

24. A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years

Author

Antrobus, Richard D., primary, Lillie, Patrick J., additional, Berthoud, Tamara K., additional, Spencer, Alexandra J., additional, McLaren, James E., additional, Ladell, Kristin, additional, Lambe, Teresa, additional, Milicic, Anita, additional, Price, David A., additional, Hill, Adrian V. S., additional, and Gilbert, Sarah C., additional

Published
2012
Full Text
View/download PDF

28. Fusion of the Mycobacterium tuberculosis Antigen 85A to an Oligomerization Domain Enhances Its Immunogenicity in Both Mice and Non-Human Primates

Author

Spencer, Alexandra J., primary, Hill, Fergal, additional, Honeycutt, Jared D., additional, Cottingham, Matthew G., additional, Bregu, Migena, additional, Rollier, Christine S., additional, Furze, Julie, additional, Draper, Simon J., additional, Søgaard, Karen C., additional, Gilbert, Sarah C., additional, Wyllie, David H., additional, and Hill, Adrian V. S., additional

Published
2012
Full Text
View/download PDF

30. Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

Author

Sheehy, Susanne H., primary, Duncan, Christopher J. A., additional, Elias, Sean C., additional, Biswas, Sumi, additional, Collins, Katharine A., additional, O'Hara, Geraldine A., additional, Halstead, Fenella D., additional, Ewer, Katie J., additional, Mahungu, Tabitha, additional, Spencer, Alexandra J., additional, Miura, Kazutoyo, additional, Poulton, Ian D., additional, Dicks, Matthew D. J., additional, Edwards, Nick J., additional, Berrie, Eleanor, additional, Moyle, Sarah, additional, Colloca, Stefano, additional, Cortese, Riccardo, additional, Gantlett, Katherine, additional, Long, Carole A., additional, Lawrie, Alison M., additional, Gilbert, Sarah C., additional, Doherty, Tom, additional, Nicosia, Alfredo, additional, Hill, Adrian V. S., additional, and Draper, Simon J., additional

Published
2012
Full Text
View/download PDF

34. Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909

Author

Duncan, Christopher J. A., primary, Sheehy, Susanne H., additional, Ewer, Katie J., additional, Douglas, Alexander D., additional, Collins, Katharine A., additional, Halstead, Fenella D., additional, Elias, Sean C., additional, Lillie, Patrick J., additional, Rausch, Kelly, additional, Aebig, Joan, additional, Miura, Kazutoyo, additional, Edwards, Nick J., additional, Poulton, Ian D., additional, Hunt-Cooke, Angela, additional, Porter, David W., additional, Thompson, Fiona M., additional, Rowland, Ros, additional, Draper, Simon J., additional, Gilbert, Sarah C., additional, Fay, Michael P., additional, Long, Carole A., additional, Zhu, Daming, additional, Wu, Yimin, additional, Martin, Laura B., additional, Anderson, Charles F., additional, Lawrie, Alison M., additional, Hill, Adrian V. S., additional, and Ellis, Ruth D., additional

Published
2011
Full Text
View/download PDF

35. Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1

Author

Biswas, Sumi, primary, Dicks, Matthew D. J., additional, Long, Carole A., additional, Remarque, Edmond J., additional, Siani, Loredana, additional, Colloca, Stefano, additional, Cottingham, Matthew G., additional, Holder, Anthony A., additional, Gilbert, Sarah C., additional, Hill, Adrian V. S., additional, and Draper, Simon J., additional

Published
2011
Full Text
View/download PDF

37. Correction: MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques

Author

Verreck, Frank A. W., primary, Vervenne, Richard A. W., additional, Kondova, Ivanela, additional, van Kralingen, Klaas W., additional, Remarque, Edmond J., additional, Braskamp, Gerco, additional, van der Werff, Nicole M., additional, Kersbergen, Ariena, additional, Ottenhoff, Tom H. M., additional, Heidt, Peter J., additional, Gilbert, Sarah C., additional, Gicquel, Brigitte, additional, Hill, Adrian V. S., additional, Martin, Carlos, additional, McShane, Helen, additional, and Thomas, Alan W., additional

Published
2011
Full Text
View/download PDF

39. Correction: Evidence of Blood Stage Efficacy with a Virosomal Malaria Vaccine in a Phase IIa Clinical Trial

Author

Thompson, Fiona M., primary, Porter, David W., additional, Okitsu, Shinji L., additional, Westerfeld, Nicole, additional, Vogel, Denise, additional, Todryk, Stephen, additional, Poulton, Ian, additional, Correa, Simon, additional, Hutchings, Claire, additional, Berthoud, Tamara, additional, Dunachie, Susanna, additional, Andrews, Laura, additional, Williams, Jack L., additional, Sinden, Robert, additional, Gilbert, Sarah C., additional, Pluschke, Gerd, additional, Zurbriggen, Rinaldo, additional, and Hill, Adrian V. S., additional

Published
2011
Full Text
View/download PDF

40. Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa

Author

Brookes, Roger H., primary, Hill, Philip C., additional, Owiafe, Patrick K., additional, Ibanga, Hannah B., additional, Jeffries, David J., additional, Donkor, Simon A., additional, Fletcher, Helen A., additional, Hammond, Abdulrahman S., additional, Lienhardt, Christian, additional, Adegbola, Richard A., additional, McShane, Helen, additional, and Hill, Adrian V. S., additional

Published
2011
Full Text
View/download PDF

47. MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques

Author

Verreck, Frank A. W., primary, Vervenne, Richard A. W., additional, Kondova, Ivanela, additional, van Kralingen, Klaas W., additional, Remarque, Edmond J., additional, Braskamp, Gerco, additional, van der Werff, Nicole M., additional, Kersbergen, Ariena, additional, Ottenhoff, Tom H. M., additional, Heidt, Peter J., additional, Gilbert, Sarah C., additional, Gicquel, Brigitte, additional, Hill, Adrian V. S., additional, Martin, Carlos, additional, McShane, Helen, additional, and Thomas, Alan W., additional

Published
2009
Full Text
View/download PDF

48. Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa

Author

Brookes, Roger H., primary, Hill, Philip C., additional, Owiafe, Patrick K., additional, Ibanga, Hannah B., additional, Jeffries, David J., additional, Donkor, Simon A., additional, Fletcher, Helen A., additional, Hammond, Abdulrahman S., additional, Lienhardt, Christian, additional, Adegbola, Richard A., additional, McShane, Helen, additional, and Hill, Adrian V. S., additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results